Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Gains from Investment Securities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Gains from Investment Securities for 5 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 646.36% to -$2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $572000.0, a N/A change, with the full-year FY2025 number at $572000.0, changed N/A from a year prior.
  • Gains from Investment Securities was -$2.6 million for Q4 2025 at Lexicon Pharmaceuticals, down from $1.6 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.9 million in Q2 2024 to a low of -$2.6 million in Q4 2025.
  • A 3-year average of $155111.1 and a median of $572000.0 in 2025 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 174.13% in 2025; the steepest drop was 646.36% in 2025.
  • Lexicon Pharmaceuticals' Gains from Investment Securities stood at $824000.0 in 2023, then crashed by 41.63% to $481000.0 in 2024, then crashed by 646.36% to -$2.6 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Gains from Investment Securities are -$2.6 million (Q4 2025), $1.6 million (Q3 2025), and $989000.0 (Q2 2025).